Frontiers in Immunology (Dec 2021)

Strategies to Circumvent the Side-Effects of Immunotherapy Using Allogeneic CAR-T Cells and Boost Its Efficacy: Results of Recent Clinical Trials

  • Sergei Smirnov,
  • Alexey Petukhov,
  • Alexey Petukhov,
  • Ksenia Levchuk,
  • Sergey Kulemzin,
  • Sergey Kulemzin,
  • Alena Staliarova,
  • Kirill Lepik,
  • Kirill Lepik,
  • Oleg Shuvalov,
  • Andrey Zaritskey,
  • Alexandra Daks,
  • Alexandra Daks,
  • Olga Fedorova,
  • Olga Fedorova

DOI
https://doi.org/10.3389/fimmu.2021.780145
Journal volume & issue
Vol. 12

Abstract

Read online

Despite the outstanding results of treatment using autologous chimeric antigen receptor T cells (CAR-T cells) in hematological malignancies, this approach is endowed with several constraints. In particular, profound lymphopenia in some patients and the inability to manufacture products with predefined properties or set of cryopreserved batches of cells directed to different antigens in advance. Allogeneic CAR-T cells have the potential to address these issues but they can cause life-threatening graft-versus-host disease or have shorter persistence due to elimination by the host immune system. Novel strategies to create an “off the shelf” allogeneic product that would circumvent these limitations are an extensive area of research. Here we review CAR-T cell products pioneering an allogeneic approach in clinical trials.

Keywords